
Danaher Corporation company profile
$229.91−1.33%Close 16 Nov 2026 · Market value $159.0B
About Danaher Corporation
Danaher Corporation is a science and technology company with three operating segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment provides equipment, consumables, software and services used in the research, development, manufacture and delivery of biological medicines, through its bioprocessing and discovery and medical businesses. The Life Sciences segment offers instruments, consumables, services and software used to study cells, proteins and nucleic acids, along with filtration products for liquids and gases. The Diagnostics segment supplies clinical instruments, consumables, software and services used by hospitals, physicians' offices and reference laboratories to diagnose disease. Customers include pharmaceutical and biotechnology companies, research institutions, laboratories and healthcare providers. Facilities for research, manufacturing, sales, distribution and service are located in approximately 50 countries.
A summary of the business section of the company's latest annual report, filed 24 Feb 2026.
Company facts
| Ticker | DHR · NYSE |
|---|
| Sector | Instruments |
|---|
| Industry | Life Sciences Tools & Services |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 313616 |
|---|
| Latest annual report | 10-K, filed 24 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Matthew R. McGrew | Executive Vice President | 231K · < 1% | Option exercise, 9 Nov 2026 |
|---|
| Christopher P. Riley | Executive Vice President | 117K · < 1% | Grant or award, 4 Aug 2026 |
|---|
| Alan G. Spoon | Director | 106K · < 1% | Grant or award, 15 May 2026 |
|---|
| Julie Sawyer Montgomery | Executive Vice President | 98.8K · < 1% | Grant or award, 1 Mar 2026 |
|---|
| John T. Schwieters | Director | 61.8K · < 1% | Shares withheld for tax, 15 Jul 2025 |
|---|
| Jose-Carlos Gutierrez-Ramos | SVP, Chief Science Officer | 60.4K · < 1% | Grant or award, 4 Aug 2026 |
|---|
| Elias A. Zerhouni, MD | Director | 37.3K · < 1% | Shares withheld for tax, 15 Jul 2026 |
|---|
| Raymond C. Stevens, Ph.D. | Director | 15.2K · < 1% | Grant or award, 15 May 2026 |
|---|
| A. Shane Sanders | Director | 9.0K · < 1% | Grant or award, 15 May 2026 |
|---|
| Milosevich Gregory M | Executive Vice President | — | Open-market sale, 9 Nov 2026 |
|---|
| Bouda Christopher | VP, Chief Accounting Officer | — | Option exercise, 28 Oct 2026 |
|---|
| RALES MITCHELL P | Chairman of Exec. Committee · Director | — | Disposition to the issuer, 9 Oct 2026 |
|---|
| RALES STEVEN M | Chairman · Director | — | Disposition to the issuer, 9 Oct 2026 |
|---|
| Blair Rainer | President & CEO · Director | — | Open-market sale, 21 Aug 2026 |
|---|
| FILLER LINDA | Director | — | Shares withheld for tax, 15 Jul 2026 |
|---|
| Couchara Georgeann | SVP, Human Resources | — | Shares withheld for tax, 15 May 2026 |
|---|
| List Teri | Director | — | Grant or award, 15 May 2026 |
|---|
| Dewan Feroz | Director | — | Grant or award, 15 May 2026 |
|---|
| Lamanna Charles W | Director | — | Grant or award, 15 May 2026 |
|---|
| Leiken Jonathan | SVP-Chief Legal Officer | — | Grant or award, 1 Mar 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
DHR in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.